Marta Ayala‐Ávila

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

Francisco Hernández‐Bernal, Maria C. Ricardo-Cobas, Yenima Martín‐Bauta et al. · EClinicalMedicine · 2022 · 69 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen

Miladys Limonta‐Fernández, Glay Chinea-Santiago, Alejandro Miguel Martín-Dunn et al. · New Biotechnology · 2022 · 57 citations · Full text

Life Sciences, Biotechnology, Immunology +17

Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial

Jorge Gavilondo, Francisco Hernández‐Bernal, Marta Ayala‐Ávila et al. · Vaccine · 2014 · 53 citations

Medicine, Immunology, Oncology +17

CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors

Mónica Béquet‐Romero, Marta Ayala‐Ávila, Julio Ancízar et al. · Vaccine · 2012 · 37 citations

Medicine, Cancer Biology, Oncology +16

Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3

Olivia Cabanillas-Bernal, Salvador Dueñas, Marta Ayala‐Ávila et al. · PLoS ONE · 2019 · 37 citations · Full text

Life Sciences, Biotechnology, Immunology +9